首页> 外文期刊>Acta Cardiologica >Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS).
【24h】

Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS).

机译:泛欧洲对高胆固醇血症治疗不足的集中调查(CEPHEUS)。

获取原文
获取原文并翻译 | 示例
       

摘要

The CEntralized Pan-European survey on tHE Under-treatment of hypercholeSterolaemia (CEPHEUS) was initiated to quantify the degree of under-treatment of hypercholesterolaemia in Europe. Its primary objective was to establish the proportion of treated patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines. Secondary objectives targeted subgroups of primary or secondary prevention patients and those with a metabolic syndrome. Further-more, CEPHEUS also aimed at the identification of determinants for under-treatment. Among the patients available for evaluation in Belgium (n=6276), 58.5% reached LDL-C goals as recommended by the 2003 European guidelines, 59.8% in primary prevention, 55.8% in secondary prevention, and 55.8% of those with a metabolic syndrome. The majority of patients (82.5%) was treated with statins. The univariate significant (P < 0.10) predictors of attaining LDL-C goal were the following: (a) nonsmoker, (b) no history of PAD or CAD, (c) absence of metabolic syndrome, (d) lower CV risk category, (e) absence of patient's concerns about treatment changes, (f) no withdrawal of lipid-lowering therapy when on target, (g) optimal. treatment adherence, (h) no patient's frustrations, (i) lipid-monitoring frequency, (j) physician being a specialist and (k) physicians finding it stressful to get patients on target. In an adjusted multi-level model, achievement of the LDL-C goals was significantly associated with: (a) type of lipid-lowering therapy, (b) risk category the patient fell into, (c) LDL-C level before initiating treatment, (d) patient's feelings about the treatment, (e) patient's acknowledgement about current cholesterol level and (f) self-reported drug compliance.
机译:发起了对高胆固醇血症(CEPHEUS)治疗不足的集中泛欧调查,以量化欧洲高胆固醇血症治疗不足的程度。其主要目的是根据第三欧洲联合特遣部队准则确定达到LDL-C目标的接受治疗的患者比例。次要目标是针对一级或二级预防患者以及代谢综合征患者的亚组。此外,CEPHEUS还旨在确定待治疗的决定因素。在比利时可评估的患者中(n = 6276),达到2003年欧洲指南推荐的LDL-C目标的58.5%,一级预防的59.8%,二级预防的55.8%和代谢综合征的55.8% 。大多数患者(82.5%)接受他汀类药物治疗。达到LDL-C目标的单因素显着(P <0.10)预测指标如下:(a)不吸烟者,(b)没有PAD或CAD病史,(c)没有代谢综合征,(d)较低的CV风险类别, (e)患者无需担心治疗变化,(f)达到目标时不撤消降脂治疗,(g)最佳。依从性,(h)没有患者的挫败感,(i)脂质监测频率,(j)内科医生为专科医生和(k)内科医生感到让患者达到目标压力很大。在调整后的多水平模型中,LDL-C目标的实现与以下因素显着相关:(a)降脂治疗的类型,(b)患者属于的危险类别,(c)开始治疗前的LDL-C水平,(d)患者对治疗的感觉,(e)患者对当前胆固醇水平的认可和(f)自我报告的药物依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号